Physician profile
Bennett P Hogan
NPI 1205891397
$2,162.43
in general payments reported to CMS, 2019-2025
30 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $371 · 2021: $178 · 2022: $228 · 2023: $408 · 2024: $459 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $334.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $170.80 | 2019-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $159.24 | 2019-2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $126.46 | 2022-2024 | Quviviq |
| Abbvie INC. | $124.03 | 2023-2025 | |
| Abbott Laboratories | $117.63 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $117.28 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Lilly USA, LLC | $111.19 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Eisai INC. | $97.75 | 2020-2022 | |
| Amgen INC. | $80.26 | 2023-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $75.88 | 2019-2024 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.26 | 2023 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.14 | 2019-2021 | |
| Dexcom, INC. | $55.86 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $55.80 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.89 | 2020-2025 | |
| Biogen, INC. | $36.61 | 2020-2021 | |
| Horizon Therapeutics Plc | $36.38 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.52 | 2022 | |
| Amarin Pharma, INC. | $33.84 | 2019-2020 | |
| Neos Therapeutics, LP | $33.17 | 2019-2020 | |
| Exact Sciences Corporation | $30.93 | 2025 | The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $30.32 | 2022-2024 | |
| Pacira Pharmaceuticals Incorporated | $22.02 | 2024 | Zilretta, Iovera |
| Kowa Pharmaceuticals America, INC. | $21.86 | 2022 | |
| Corium, LLC | $16.99 | 2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $16.77 | 2019 | |
| Genentech USA, INC. | $13.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.55 | 2020 | |
| Allergan, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennett Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.